Infections in rheumatoid arthritis

Current Opinion in Rheumatology

Volumn 29, Issue 4, 2017, Pages 323-330

  Atzeni, Fabiola ^a   Masala, Ignazio Francesco ^b   Di Franco, Manuela ^c   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SS Trinit Hospital   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

anti tumour necrosis factor drugs; fungal and viral infections; infections; newer biological drugs; orthopaedic surgery; perioperative infections

Indexed keywords

BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

BACTERIAL ARTHRITIS; BACTERIAL INFECTION; EVIDENCE BASED PRACTICE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES ZOSTER; HUMAN; INFECTION; INFECTIOUS ARTHRITIS; META ANALYSIS (TOPIC); MYCOSIS; NONHUMAN; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW (TOPIC); TUBERCULOSIS; RISK FACTOR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INFECTION; RISK FACTORS;

EID: 85017631090     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000389     Document Type: Review

References (80)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903-911.
2. Mikuls TR, Saag KG, Criswell LA, et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis 2002; 61: 994-999.
3. Baum J. Infections in rheumatoid arthritis. Arthritis Rheum 1971; 14: 135-137.
4. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls. A population-based study. Arthritis Rheum 2002; 9: 2287-2293.
5. Atzeni F, Bendtzen K, Bobbio-Pallavicini F, et al. Infections and treatment of patients with rheumatic diseases. Clin Exp Rheumatol 2008; 26: S67-73.
6. Carmona L, Cross M, Williams B, et al. Rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010; 24: 733-745.
7. Brassard P, Kezouh A, Suissa S, et al. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43: 717-722.
8. van der Veen MJ, van der Heide A, Kruize AA, et al. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994; 53: 224-248.
9. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006; 45: 1370-1375.
10. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic diseasemodifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59: 1074-1081.
11. Bernatsky S, Hudson M, Suissa S. Antirheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1157-1160.
12. LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 1994; 150: 258-260.
13. Jenks KA, Stamp LK, O'Donnell JL, et al. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol 2007; 34: 2201-2203.
14. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, diseasemodifying antirheumatic drugs, and antitumor necrosis factor therapy. Arthritis Rheum 2006; 54: 628-634.
15. Grennan DM, Gray J, Loudon J, et al. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001; 60: 214-217.
16. Edwards CJ, Cooper C, Fisher D, et al. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 1151-1157.
17. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009; 68: 1086-1093.
18. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2001; 63: 1479-1485.
19. Lahiri M, Dixon WG. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol 2015; 29: 290-305.
20. Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol 2008; 220: 443-449.
21. Dittmar M. Human biological research since 2006 at the Christian-Albrechts-University in Kiel: aging, chronobiology, and high altitude adaptation. Anthropol Anz 2014; 71: 143-153.
22. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2: 602-610.
23. Souto A, Maneiro JR, Salgado E, et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review andmeta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 2014; 53: 1872-1885.
24. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human antitumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twentyfour-week results of a phase III, multicenter, randomized, double-blind, placebocontrolled study of golimumab before methotrexate as first-line therapy for earlyonset rheumatoid arthritis. Arthritis Rheum 2009; 60: 2272-2283.
25. Keystone EC, Combe B, Smolen J, et al. Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatol Oxford 2012; 51: 1628-1638.
26. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804.
27. Cantini F, Nannini C, Niccoli L, et al. (SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev 2015; 14: 503-509.
28. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection: United States, 2010. MMWR Recomm Rep 2010; 59: 1-25.
29. Arkema EV, Jonsson J, Baecklund E, et al. ARTIS Study Group. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis 2016; 4: 1212-1217.
30. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-2376.
31. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-3412.
32. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50: 124-131.
33. Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011; 70: 1914-1920.
34. Atzeni F, Sarzi-Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012; 12: 225-229.
35. Filippini M, Bazzani C, Favalli EG, et al. Efficacy and safety of antitumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol 2010; 38: 90-96.
36. Singh JA, Cameron C, Noorbaloochi S, et al. The risk of serious infection with biologics in treating patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 2015; 6736: 61704-61709.
37. Davies R, Dixon WG, Watson KD, et al. BSRBR Control Centre Consortium, Symmons DP, Hyrich KL; on behalf of the BSRBR. Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. Ann Rheum Dis 2013; 72: 461-462.
38. de La Forest Divonne M, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real life: a systematic literature review and meta-analyses of biologic registers. Joint Bone Spine 2017; 84: 133-140.
39. Burmester GR, Landewë R, Genovese MC, et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2017; 76: 414-417.
40. Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections complicating tumor necrosis factor a blockade therapy. Mayo Clin Proc 2008; 83: 181-189.
41. Alvarez B, Arcos J, Fernändez-Guerrero ML. Pulmonary infectious diseases in patients with primary immunodeficiency and those treated with biologic immunomodulating agents. Curr Opin Pulm Med 2011; 17: 172-179.
42. Smith JA, Kauffman CA. Endemic fungal infections in patients receiving tumor necrosis factor-a inhibitor therapy. Drugs 2009; 69: 1403-1415.
43. Liao TL, Chen YM, Chen DY. Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications. Clin Microbiol Infect 2016; 22: 815.
44. Goodman SM, Figgie MA. Arthroplasty in patients with established rheumatoid arthritis (RA): mitigating risks and optimizing outcomes. Best Pract Res Clin Rheumatol 2015; 29: 628-642.
45. Del Pozo JL, Patel R. Clinical practice. Infection associated with prosthetic joints. N Engl J Med 2009; 361: 787-794.
46. Zimmerli W, Moser C. Pathogenesis and treatment concepts of orthopaedic biofilm infections. FEMS Immunol Med Microbiol 2012; 65: 158-168.
47. Mc Conoughey SJ, Howlin R, Granger JF, et al. Biofilms in peri prosthetic orthopedic infections. Future Microbiol 2014; 9: 987-1007.
48. Goodman SM, Menon I, Christos PJ, et al. Management of perioperative tumour necrosis factor a inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. Rheumatology(Oxford) 2016; 55: 573-582.
49. Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 1810-1814.
50. Goh L, Jewell T, Laversuch C. Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int 2012; 3: 5-13.
51. Mabille C, Degboe Y, Constantin A, et al. Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNFalpha. Joint Bone Spine 2016; Sep 20. pii: S1297-319X(16)30134-8. doi: 10. 1016/j. jbspin. 2016. 06. 011. [Epub ahead of print]
52. Atzeni F, Batticciotto A, Masala IF, et al. Infections and biological therapy in patients with rheumatic diseases. IMAJ 2016; 18: 164-167.
53. Che H, Lukas C, Morel J. Risk of herpes/herpes zoster during antitumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine 2014; 81: 215-221.
54. Harpaz R, Ortega-Sanchez I, Seward J. Prevention of herpes zoster. MMWR Morb Mortal Wkly Rep 2008; 50: 1-30.
55. http: //www. who. int/csr/disease/hepatitis/HepatitisB-whocdscsrlyo2002-2. pdf. Accessed 20 July 2014.
56. Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64: 788-789.
57. Pë rez-Alvarez R, Dïaz-Lagares C, Garcïa-Hernändez F, et al. BIOGEAS Study Group. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011; 90: 359-371.
58. Cantini F, Boccia S, Goletti D, et al. HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-a) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis. Int J Rheumatol 2014; 926836.
59. Viganò M, Degasperi E, Aghemo A, et al. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther 2012; 12: 193-207.
60. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2012; 13: 2436-2441.
61. Parke FA, Reveille JD. Antitumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51: 800-804.
62. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42: 315-322.
63. Atzeni F, Sarzi-Puttini P, Mutti A, et al. Long-term safety of abatacecpt in patients with rheumatoid arthritis. Autoim Rev 2013; 12: 1115-1117.
64. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a oneyear randomized, placebo-controlled study. Arthritis Rheum 2006; 54: 2807-2816.
65. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014; 370: 2377-2386.
66. Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2012; 72 (Suppl 2): ii2-ii34.
67. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011; 50: 552-562.
68. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: metaanalyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68: 25-32.
69. Lahaye C, Soubrier M, Mulliez A, et al. French Society of Rheumatology. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry. Rheumatology (Oxford) 2016; 55: 874-882.
70. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2014; 66: 2675-2684.
71. Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75: 1843-1847.
72. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheumatol 2010; 62: 2625-2632.
73. Hirao M, Hashimoto J, Tsuboi H, et al. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis 2009; 68: 654-657.
74. Viganò M, Mangia G, Lampertico P. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. Expert Opin Biol Ther 2014; 14: 1019-1031.
75. Varisco V, Viganò M, Batticciotto A, et al. Low risk of hepatitis B virus reactivation in HBsAgnegative/Anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis: a retrospective multicenter Italian study. J Rheumatol 2016; 43: 869-874.
76. Padovan M, Filippini M, Tincani A, et al. Safety of abatacept in rheumatoid arthritis patients with serological evidence of past or present hepatitis B infection. Arthritis Care Res 2016; 68: 738-743.
77. Lin KM, Lin JC, Tseng WY, et al. Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis. J Microbiol Immunol Infect 2013; 46: 65-67.
78. Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011; 11: 48-55.
79. Mahajan TD, Hooker R, Maher L, et al. Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection. J Clin Rheumatol 2010; 16: 332-334.
80. Dragonas C, Ehrenstein B, Fleck M. Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C. infection. Rheumatology (Oxford) 2012; 51: 1520-1521.